Allergen-induced changes in the nasal mucous membrane in seasonal allergic rhinitis: Effect of nedocromil sodium

1990 ◽  
Vol 85 (1) ◽  
pp. 125-131 ◽  
Author(s):  
S LOZEWICZ ◽  
E GOMEZ ◽  
J CLAGUE ◽  
D GATLAND ◽  
R DAVIES
Keyword(s):  
Allergic Rhinitis ◽  
Mucous Membrane ◽  
Seasonal Allergic Rhinitis ◽  
Nedocromil Sodium ◽  
Nasal Mucous Membrane ◽  
Induced Changes

Lymphocyte infiltration and thickness of the nasal mucous membrane in perennial and seasonal allergic rhinitis

1994 ◽  
Vol 93 (3) ◽  
pp. 635-643 ◽  
Author(s):  
Moisés A. Calderón ◽  
Stefan Lozewicz ◽  
Andrew Prior ◽  
Susan Jordan ◽  
Cecilia J. Trigg ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Mucous Membrane ◽  
Seasonal Allergic Rhinitis ◽  
Lymphocyte Infiltration ◽  
Nasal Mucous Membrane

The Efficacy and Safety of Nedocromil Sodium 1% Nasal Solution in the Treatment of Ragweed Seasonal Allergic Rhinitis

1991 ◽  
Vol 5 (6) ◽  
pp. 241-248 ◽  
Author(s):  
Howard J. Schwartz ◽  
Lorraine D. Ellis ◽  
Theodore H. Sher
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Sleep Disturbances ◽  
Drug Efficacy ◽  
Baseline Period ◽  
Nedocromil Sodium ◽  
Double Blind ◽  
Runny Nose ◽  
Nasal Irritation ◽  
Adverse Experiences

The safety and efficacy of nedocromil sodium 1% nasal solution in the treatment of patients with ragweed seasonal allergic rhinitis was assessed in a double-blind group-comparative study. After a 1-week baseline period that coincided with the start of the ragweed season, patients were randomized to receive either nedocromil sodium 1% nasal solution or matched placebo (1 spray per nostril q.i.d.) for 8 weeks. The primary efficacy variable was the mean daily diary card symptom score for the 3-week peak pollen period. During this time, patients treated with nedocromil sodium showed a significant decrease in sneezing, runny nose symptoms, and sleep disturbances compared with the placebo group. Furthermore, the patient's and physician's assessments of the drug efficacy showed significant differences favoring the nedocromil sodium treatment. No serious adverse experiences were reported during the study. Both groups reported transient minor adverse experiences including sneezing and nasal irritation. Nedocromil sodium was effective in relieving symptoms associated with seasonal allergic rhinitis during peak ragweed seasonal challenge without significant adverse effects.

Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis

2006 ◽  
Vol 96 (5) ◽  
pp. 673-678 ◽  
Author(s):  
Constantinos Pitsios ◽  
Dimitrios Papadopoulos ◽  
Evangelia Kompoti ◽  
Emmanouel Manoussakis ◽  
Viktor Garris ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Prophylactic Treatment ◽  
Mometasone Furoate ◽  
Nedocromil Sodium ◽  
Efficacy And Safety

scholarly journals Topical glucocorticosteroids in the treatment of patients with allergic rhinitis

2019 ◽  
pp. 94-97
Author(s):  
A. Yu. Ovchinnikov ◽  
N. A. Miroshnichenko ◽  
I. V. Smirnov
Keyword(s):  
Allergic Rhinitis ◽  
Mucous Membrane ◽  
Inflammatory Cells ◽  
Developed Countries ◽  
The Body ◽  
Common Disease ◽  
Upper Respiratory Tract ◽  
Inflammatory Infiltration ◽  
Nasal Mucous Membrane ◽  
The Impact

Allergic rhinitis (AR) is a common disease that affects people regardless of age, place of residence or social status. As a rule, the allergen enters the body through the upper respiratory tract, the entrance gate is mainly the nasal mucous membrane. According to statistics, in recent years the frequency of perennial AR (PAR) in economically developed countries has been approaching 40-50%. In AR, inflammatory infiltration of the nasal mucous membrane by various cells is observed. Nowadays, AR is characterized by early onset, often with continuous relapsing course and resistance to antiallergic therapy. The study of the mechanisms of disease development creates the basis for rational therapy, which involves the impact on a complex inflammatory response, not only on the symptoms of allergy. Therefore, timely conservative therapy with intranasal topical glucocorticosteroid is advisable. The article shows the importance of the effectiveness of Flixonase intranasal spray in the treatment of AR. This drug may be recommended for the treatment of PAR. Studies of the use of the drug have shown a multi-purpose mechanism of its action. Flixonase significantly reduces the number of inflammatory cells in the nasal mucous membrane and inhibits the action of local inflammatory mediators in both seasonal ARs and PARs. To achieve the best results, the drug should be used at the first signs of nascent AR.

Sign in / Sign up

Export Citation Format

Share Document